This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
Kyowa Kirin AMD
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients with Neovascular Age-Related Macular Degeneration.
Overview
The Kyowa Kirin AMD trial is testing a new potential treatment for Neovascular AMD (nAMD) also known as Wet AMD.
nAMD is a prevalent, progressive retinal eye disease that is characterised by new blood vessel formation in the choroid (a layer of tissue in the eye that is filled with blood vessels), mainly affecting the elderly population. Leaking of fluid from these new blood vessels in the eye may result in loss of vision.
Vascular endothelial growth factor (VEGF) is a protein that plays a significant role in new blood vessel growth. KHK4951 eye drops are expected to inhibit activation of VEGF and will be given to participants in this study. Standard-of-care drug aflibercept will also be given during a run-in period and as rescue treatment. The 3 treatment groups are KHK4951 0.15mg or placebo twice daily, KHK4951 0.6mg or placebo twice daily and KHK4951 1.2mg twice daily.
For further information about this study, please contact Cerulea on (03) 86385300 or email info@ceruleaclinicaltrials.org.au.
- Principal Investigator
Associate Professor Sanj Wickremasinghe
The Kyowa Kirin AMD trial is testing a new potential treatment for Neovascular AMD (nAMD) also known as Wet AMD.
nAMD is a prevalent, progressive retinal eye disease that is characterised by new blood vessel formation in the choroid (a layer of tissue in the eye that is filled with blood vessels), mainly affecting the elderly population. Leaking of fluid from these new blood vessels in the eye may result in loss of vision.
Vascular endothelial growth factor (VEGF) is a protein that plays a significant role in new blood vessel growth. KHK4951 eye drops are expected to inhibit activation of VEGF and will be given to participants in this study. Standard-of-care drug aflibercept will also be given during a run-in period and as rescue treatment. The 3 treatment groups are KHK4951 0.15mg or placebo twice daily, KHK4951 0.6mg or placebo twice daily and KHK4951 1.2mg twice daily.
For further information about this study, please contact Cerulea on (03) 86385300 or email info@ceruleaclinicaltrials.org.au.
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.